Skip to main content
. 2021 Apr 23;7(17):eabg4038. doi: 10.1126/sciadv.abg4038

Fig. 3. Tumor onset suppression via cRGD-based SeCT therapy.

Fig. 3

(A) Using the cRGD-PE reagent, this application is based on the indiscriminate tagging of cancer cell surface proteins with a cRGD moiety. Overexpressed integrins on cell surfaces will be exposed to a higher localized concentration of the inhibitor, leading to the disruption of integrin-based cell adhesion and the reduction in tumor onset and progression. (B) HeLa cell proliferation assay showing the nontoxic nature of the SeCT labeling reagents at various time points (0, 3, 24, and 48 hours) compared with a negative control. P values were determined by one-way analysis of variance (ANOVA). (C) Cell adhesion assay of HeLa cells to fibronectin-coated plates treated with SeCT labeling reagents. P values were determined by paired t test. All numerical data are presented as means ± SEM of three replicates. *P < 0.05, **P < 0.01, and ***P < 0.001; n.s., not significant.